BCSP, Psychedelic Alpha, and Calyx Law Launch Psychedelic Law and Policy Tracker

law and policy map of the United States
Explore the map here.

The UC Berkeley Center for the Science of Psychedelics, Psychedelic Alpha, and Calyx Law have collaborated on an interactive law and policy map to monitor the rapidly evolving landscape of psychedelic legislation across the United States. This visual tool aims to provide real-time updates on state-level bills and initiatives focused on decriminalization and legal access to psychedelic therapies.

As the field of psychedelic research gains momentum, an increasing number of states are considering reforms to existing drug policies. The law and policy map will offer researchers, policymakers, and the public a clear, at-a-glance view of where changes occur and what specific measures are being proposed or enacted.

Through the map, visitors can view a state’s milestone legislation or attempted legislation, explore local reforms, and track initiatives in cities across the U.S. The key also enables visitors to filter by type, including decriminalization and judicial exception, and to compare failed and active legislation.

The BCSP maintains this map in collaboration with Psychedelic Alpha and Calyx Law. Psychedelic Alpha is an independent media outlet, community, and consultancy firm that strives to empower a diverse constellation of individuals and organizations with the knowledge, network, and nuance to make an impact within the field of psychedelic medicine and beyond. Calyx Law is a boutique law firm focusing on psychedelics and emerging technologies.

Calyx Law

Calyx Law, established in 2016, is a boutique law firm specializing in psychedelics and emerging technologies. While a flower is budding, it is protected by a whorl of sepals that enclose the flower as it emerges and provide stability as it opens. This structure is the calyx. Like a calyx, Calyx Law sees its role as providing seed-stage and early-stage companies with the protection and support they need to come into full bloom, primarily through the strategic use of patents and other intellectual property to generate value and spur growth.

Psychedelic Alpha

Psychedelic Alpha is an independent media outlet, community, and consultancy firm that strives to empower a diverse constellation of individuals and organizations with the knowledge, network, and nuance to make an impact within the field of psychedelic medicine and beyond.

Through its trusted resources, timely analyses, and contributions from subject matter experts it seeks to cut through the noise and explore how we might address the clinical, cultural, and cost-based barriers to the potential roll-out of psychedelic therapies.

Organizer’s Handbook

The Organizer’s Handbook is a living, evolving collection of organizing principles, guides, tools, and research. These documents have been created by the Decriminalize Nature National Board and local DN organizations, and act as a starting point for those who seek to organize their own communities, and contribute to and become part of the movement to re-establish our direct relationship to consciousness-healing plants and fungi.

A Psychedelic Renaissance: Historical Reflections on the Future

In February 2014 Scientific American shocked readers with an editorial that called for an end to the ban on psychedelic drug research.1 The article criticized the mental health treatment industry for failing to advance therapies beyond the golden era of the 1950s, and lambasted drug regulators for prohibiting psychedelic drugs, including LSD, ecstasy (MDMA), and psilocybin; drugs, which had historically held clinical promise but were “designated as drugs of abuse.”2 As the editors pointed out, the situation has created a paradox: “these drugs are banned because they have no accepted medical use, but researchers cannot explore their therapeutic potential because they are banned….The decades-long research hiatus has taken its toll.”3 Lest there be any confusion as to where the editors stood on the issue, they continued with explicit instructions: “This is a shame. The US government should move these drugs to the less strict Schedule II classification…it would make it much easier for clinical researchers to study their effects.”4 The article brought public and scientific attention to a growing contention amongst researchers, and even some regulators, that the clinical potential among psychedelic drugs had been dismissed due to a moral panic about drug abuse.

Decriminalisation in Portugal: Setting the Record Straight.

What you need to know:

-Drug-related deaths have remained below the EU average since 2001
-The proportion of prisoners sentenced for drugs has fallen from 40% to 15%
-Rates of drug use have remained consistently below the EU average

This briefing updates our 2016 report on Portugal’s groundbreaking reforms, and marks the 20th anniversary of their introduction.

Bipartisan Majority Of Americans Support Drug Decriminalization, And Most Favor Overdose Prevention Sites, Poll Finds

A strong majority of Americans, including most Republicans, support drug decriminalization, according to a new national poll released on Friday. There’s also majority support overall for allowing the operation of overdose prevention centers where people can use illicit substances in a medically supervised setting and receive treatment resources.

The survey from Data For Progress and the People’s Action Institute asked a wide range of questions about harm reduction proposals, finding that likely voters broadly support bold policy changes to address the overdose crisis.

Psychedelic Legalization & Decriminalization Tracker

As the psychedelic renaissance contributes to a swelling pool of safety and efficacy data pertaining to the potential therapeutic benefits of psychedelic medicine, many localities—particularly in North America—are revising their legal frameworks. This is happening in a number of ways: from the least rigorous incarnation which involves making the enforcement of psychedelics’ illegality the lowest law enforcement priority in a given city (such as in Washington, DC), right through to state-wide legalization of specific psychedelics (such as in Oregon). A number of U.S. cities and states have moved to loosen the consequences for personal use or small, noncommercial amounts of psychedelics. Denver, CO became the first city in May 2019, with two Californian cities—Oakland and Santa Cruz—following suit. Psilocybin and psychedelic drugs are still illegal in those jurisdictions under state law, so it is inaccurate to say it is “decriminalized.” But those local governments have taken steps to deprioritize enforcing criminal penalties there.The map below seeks to track these initiatives.

The Cure for America’s Opioid Crisis? End the War on Drugs

The War on Drugs. What began as a battle waged on morals has in fact created multiple public health crises, and no recent phenomenon illustrates this in more macabre detail than America’s opioid disaster. Last year alone amassed a higher death toll than the totality of American military casualties in the Vietnam, Iraq, and Afghanistan wars combined. With this wave of mortalities came an accompanying tidal crash of parens patriae lawsuits filed by states, counties, and cities on the theory that jurisdictions are entitled to recompense for the costs of addiction ostensibly created by Big Pharma. To those attuned to the failures of the Iron Law of Prohibition, this litigation-fueled blame game functions merely as a Band-Aid over a deeply infected wound. This Article synthesizes empirical economic impact data to paint a clearer picture of the role that drug prohibition has played in the devastation of American communities, exposes parens patriae litigation as a misguided attempt at retribution rather than deterrence, and calls for the legal and political decriminalization of opiates. We reveal that America’s fear of decriminalization has at its root the “chemical hook” fallacy—a holdover from Nancy Reagan-era drug policy that has been debunked by far less wealthy countries like Switzerland and Portugal, whose economies have already benefited from discarding the War on Drugs as an irrational and expensive approach to public health. We argue that the legal and political acceptance of addiction as a public health issue—not the view that addiction is a moral failure to scourge—is the only rational, fiscally responsible option left to a country that badly needs both a prophylactic against future waves of heavy opioid casualties, and restored faith in its own criminal justice system. Keywords: drug policy, prescription drugs, illicit drugs, heroin, addiction, black market, pharmaceuticals, fentanyl, legalization, taxation, opioids, opioid crisis, war on drugs, drug decriminalization

>